Literature DB >> 33708430

Combined targeting of vascular endothelial growth factor C (VEGFC) and P65 using miR-27b-3p agomir and lipoteichoic acid in the treatment of gastric cancer.

Yejia Cui1, Shaolong Huang1,2, Jin Cao1, Jinjun Ye1, Haohai Huang3, Dan Liao4, Yufeng Yang5, Wanchan Chen1, Rong Pu1.   

Abstract

BACKGROUND: Gastric cancer is the second leading cancer-related mortality worldwide and more effective treatment strategies are urgently needed to combat the disease. Using lipoteichoic acid (LTA) and miR-27b-3p agomir, we aimed to assess the efficacy of this combination of therapies in treating gastric cancer.
METHODS: The RNA levels of miR-27b-3p, FOXO3, MET, KRAS, vascular endothelial growth factor C (VEGFC), TSC1, and P65 were analyzed by quantified-PCR (Q-PCR) and the cell viability of AGS cells was analyzed by MTT. Confirm Luciferase reporter assays were used to explore the putative miR-27b-3p binding sites and Western blot analyzed the protein level of GAPDH, VEGFC, P65, AKT, and phosphorylated-AKT (p-AKT). The level of P65 in both the cytoplasm and nucleus of AGS cells was visualized by immunofluorescence assay. Subcutaneous xenograft models of gastric cancer were established, and mice were treated with miR-27b-3p agomir, LTA, or both. Hematoxylin-eosin staining and Ki-67 immunohistochemistry analysis of tumor tissues were then performed.
RESULTS: The results showed that the decreased expression of miR-27b-3p in gastric cancer cell lines inhibited the viability of AGS cells, and VEGFC was confirmed as the target of miR-27b-3p. In addition, ectopic expression of miR-27b-3p significantly inhibited the AKT pathway in AGS and N87 cells, and LTA suppressed the proliferation of gastric cancer cells by inhibiting the NF-κB pathway. In an established xenograft model, both miR-27b-3p agomir alone and LTA treatment alone inhibited tumor growth and treatment which combined the two showed an even stronger inhibitory effect.
CONCLUSIONS: Taken together, the combined use of LTA and miR-27b-3p agomir exhibited a synergistic effect in the treatment of gastric cancer. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Akt; NF-κB; apoptosis; gastric cancer; miR-27b-3p; vascular endothelial growth factor C (VEGFC)

Year:  2021        PMID: 33708430      PMCID: PMC7944161          DOI: 10.21037/jgo-21-12

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  40 in total

1.  Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.

Authors:  Maeva Dufies; Sandy Giuliano; Damien Ambrosetti; Audrey Claren; Papa Diogop Ndiaye; Michalis Mastri; Walid Moghrabi; Lindsay S Cooley; Marc Ettaiche; Emmanuel Chamorey; Julien Parola; Valerie Vial; Marilena Lupu-Plesu; Jean Christophe Bernhard; Alain Ravaud; Delphine Borchiellini; Jean-Marc Ferrero; Andréas Bikfalvi; John M Ebos; Khalid Saad Khabar; Renaud Grépin; Gilles Pagès
Journal:  Cancer Res       Date:  2017-01-13       Impact factor: 12.701

Review 2.  Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.

Authors:  Parisa Karimi; Farhad Islami; Sharmila Anandasabapathy; Neal D Freedman; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-11       Impact factor: 4.254

3.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

4.  Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.

Authors:  Ning Xie; Yue Wang; Qiang Wang; Fu-rong Li; Bin Guo
Journal:  Bull Cancer       Date:  2012-05       Impact factor: 1.276

Review 5.  MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer.

Authors:  Jianbo Wang; Qingwei Wang; Hong Liu; Bo Hu; Wei Zhou; Yufeng Cheng
Journal:  Cancer Lett       Date:  2010-08-24       Impact factor: 8.679

6.  MiR-122 targets VEGFC in bladder cancer to inhibit tumor growth and angiogenesis.

Authors:  Yi Wang; Qing-Fei Xing; Xiao-Qiang Liu; Zhan-Jun Guo; Chang-Ying Li; Guang Sun
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

7.  MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.

Authors:  Yan-Ran Wu; Hai-Jun Qi; Dan-Fang Deng; Ying-Ying Luo; Sheng-Lan Yang
Journal:  Tumour Biol       Date:  2016-05-17

8.  The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection.

Authors:  Jing-jing Zhao; Ke Pan; Wei Wang; Ju-gao Chen; Yan-heng Wu; Lin Lv; Jian-jun Li; Yi-bing Chen; Dan-dan Wang; Qiu-zhong Pan; Xiao-dong Li; Jian-chuan Xia
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

9.  Gastric cancer: current status of diagnosis and treatment.

Authors:  Tsunehiro Takahashi; Yoshiro Saikawa; Yuko Kitagawa
Journal:  Cancers (Basel)       Date:  2013-01-16       Impact factor: 6.639

10.  A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.

Authors:  Fumitaka Endo; Satoshi S Nishizuka; Kohei Kume; Kazushige Ishida; Hirokatsu Katagiri; Kaoru Ishida; Kei Sato; Takeshi Iwaya; Keisuke Koeda; Go Wakabayashi
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more
  2 in total

Review 1.  Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors.

Authors:  Xianhu Zeng; Zhipeng Li; Chunrong Zhu; Lisa Xu; Yong Sun; Shangcong Han
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 2.  Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?

Authors:  Christian Bailly; Xavier Thuru; Bruno Quesnel
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.